This influx of calcium at the contact site attracts and activates a kinase called CaMKII, a protein known to be important in ...

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous ...

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...

Sarcomatrix Therapeutics, Corp Logo Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 Our robust preclin ...

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...